News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
539,769 Results
Type
Article (21915)
Company Profile (357)
Press Release (517406)
Multimedia
Podcasts (241)
Webinars (20)
Section
Business (184739)
Career Advice (1083)
Deals (28612)
Drug Delivery (118)
Drug Development (62095)
Employer Resources (146)
FDA (11208)
Job Trends (10582)
News (266077)
Policy (21295)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (4)
2027 Genetown Standard (6)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (958)
Academic (1)
Accelerated approval (40)
ADA (28)
Adcomms (17)
Allergies (117)
Alliances (37528)
ALS (149)
Alzheimer's disease (1249)
Antibody-drug conjugate (ADC) (388)
Approvals (11598)
Artificial intelligence (560)
ASCO (220)
Autoimmune disease (265)
Automation (42)
Bankruptcy (300)
Best Places to Work (7776)
BIO (81)
Biologics (1)
BIOSECURE Act (17)
Biosimilars (161)
BioSpace Insights (230)
Biotechnology (229)
Bladder cancer (164)
Brain cancer (40)
Breast cancer (602)
Cancer (4468)
Cardiovascular disease (337)
Career advice (946)
Career pathing (41)
CAR-T (254)
CDC (31)
Celiac Disease (2)
Cell therapy (724)
Cervical cancer (38)
Clinical research (54324)
Collaboration (1617)
Commercialization (6)
Company closure (6)
Compensation (1472)
Complete response letters (58)
COVID-19 (1945)
CRISPR (96)
C-suite (958)
Cystic fibrosis (110)
Data (6352)
Decentralized trials (2)
Denatured (98)
Depression (139)
Dermatology (64)
Diabetes (431)
Diagnostics (4807)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (42)
Drug discovery (278)
Drug pricing (102)
Drug shortages (14)
Duchenne muscular dystrophy (227)
Earnings (78127)
Editorial (56)
Employer branding (22)
Employer resources (121)
Events (95650)
Executive appointments (850)
FDA (14085)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (21)
Frontotemporal dementia (26)
Funding (1342)
Gene editing (194)
Generative AI (50)
Gene therapy (563)
GLP-1 (728)
Government (1957)
Grass and pollen (3)
Guidances (318)
Healthcare (10517)
Hematology (115)
HIV (65)
Huntington's disease (46)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (88)
Immunology and inflammation (211)
Immuno-oncology (83)
Indications (169)
Infectious disease (2182)
Inflammatory bowel disease (153)
Inflation Reduction Act (13)
Influenza (98)
Intellectual property (271)
Interviews (176)
IPO (13477)
IRA (27)
Job creations (3014)
Job search strategy (824)
JPM (61)
Kidney cancer (17)
Labor market (125)
Layoffs (386)
Leadership (25)
Legal (5894)
Licensing (9)
Liver cancer (64)
Longevity (26)
Lung cancer (627)
Lymphoma (307)
Machine learning (45)
Management (36)
Manufacturing (838)
Marketing (8)
MASH (164)
Medical device (9259)
Medtech (9414)
Mergers & acquisitions (16223)
Metabolic disorders (1118)
mRNA (219)
Multiple sclerosis (133)
NASH (11)
Neurodegenerative disease (330)
Neuropsychiatric disorders (67)
Neuroscience (2373)
Neurotech (1)
NextGen: Class of 2026 (4095)
Non-profit (1112)
Now hiring (81)
Obesity (475)
Opinion (210)
Ovarian cancer (178)
Pain (192)
Pancreatic cancer (233)
Parkinson's disease (244)
Partnered (33)
Patents (521)
Patient recruitment (572)
Peanut (39)
People (46013)
Pharmaceutical (68)
Pharmacy benefit managers (17)
Phase 1 (17475)
Phase 2 (24414)
Phase 3 (17251)
Pipeline (8026)
Policy (235)
Postmarket research (1723)
Preclinical (7312)
Press Release (47)
Prostate cancer (216)
Psychedelics (59)
Radiopharmaceuticals (243)
Rare diseases (890)
Real estate (3929)
Recruiting (56)
Regulatory (17397)
Reports (76)
Research institute (995)
Resumes & cover letters (155)
Rett syndrome (46)
RNA editing (22)
RSV (59)
Schizophrenia (124)
Series A (259)
Series B (192)
Service/supplier (11)
Sickle cell disease (90)
Special edition (32)
Spinal muscular atrophy (109)
Sponsored (31)
Startups (2886)
State (1)
Stomach cancer (8)
Supply chain (79)
Tariffs (33)
The Weekly (140)
Vaccines (834)
Venture capital (121)
Weight loss (283)
Women's health (102)
Worklife (19)
Date
Today (115)
Last 7 days (604)
Last 30 days (1920)
Last 365 days (22541)
2026 (14012)
2025 (22342)
2024 (26552)
2023 (30004)
2022 (38938)
2021 (41426)
2020 (37027)
2019 (26635)
2018 (19930)
2017 (22249)
2016 (21520)
2015 (27140)
2014 (23926)
2013 (19895)
2012 (22019)
2011 (22098)
2010 (21748)
Location
Africa (520)
Alabama (77)
Alaska (2)
Arizona (315)
Arkansas (12)
Asia (24877)
Australia (3147)
California (12721)
Canada (3289)
China (867)
Colorado (500)
Connecticut (451)
Delaware (270)
Europe (39627)
Florida (1841)
Georgia (383)
Hawaii (5)
Idaho (51)
Illinois (835)
India (73)
Indiana (370)
Iowa (18)
Japan (439)
Kansas (115)
Kentucky (36)
Louisiana (35)
Maine (28)
Maryland (1291)
Massachusetts (8625)
Michigan (329)
Minnesota (635)
Mississippi (5)
Missouri (98)
Montana (21)
Nebraska (14)
Nevada (143)
New Hampshire (70)
New Jersey (2851)
New Mexico (21)
New York (2977)
North Carolina (1371)
North Dakota (5)
Northern California (6366)
Ohio (334)
Oklahoma (16)
Oregon (22)
Pennsylvania (2376)
Puerto Rico (23)
Rhode Island (36)
South America (692)
South Carolina (78)
South Dakota (1)
Southern California (5136)
Tennessee (131)
Texas (2088)
United States (41690)
Utah (406)
Vermont (1)
Virginia (180)
Washington D.C. (55)
Washington State (982)
West Virginia (2)
Wisconsin (85)
539,769 Results for "92bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer
July 1, 2026
·
3 min read
Business
Leveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody Platform
Leveragen, Inc. announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused on the development of therapeutic antibodies.
May 28, 2024
·
3 min read
Press Releases
Route 92 Medical Celebrates the 200th Patent for its Neurovascular Intervention Portfolio
July 20, 2026
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Pancreatic cancer
‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response
After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.
June 8, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
August 4, 2026
·
18 min read
Press Releases
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
May 18, 2026
·
2 min read
Mergers & acquisitions
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
At $9.2 billion, the Cidara acquisition lands among the top 5 largest deals of the year.
November 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 8, 2026
·
11 min read
Press Releases
Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development
June 2, 2026
·
3 min read
1 of 53,977
Next
